Posted by Michael Wonder on 23 May 2019
Biosimilars no longer reviewed through the CADTH CDR and pCODR processes
23 May 2019 - When CADTH launched a new, streamlined biosimilar review process in February 2018, we committed to evaluating the impact and utility of the new process after approximately one year.
CADTH recently completed this internal evaluation, which included consultation with public drug plans and the pan-Canadian Pharmaceutical Alliance (pCPA). As a result, CADTH is pleased to announce that there is no longer a need for CADTH to continue offering the streamlined biosimilar review process. There are no changes to the current pCPA negotiation process anticipated as a result of the decision by CADTH.
As of 1 June 2019, CADTH will be stopping work on any biosimilar reviews that would have been completed after 1 June 2019.
